Charcoal for Health & Longevity - Quick Reference Sheet

Charcoal for Health & Longevity

Created on 07/24/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

Charcoal reliably traps substances in the gut. Its strongest role is binding swallowed drugs and poisons in emergencies. It can lower certain gut-derived waste products when kidneys fail, with weaker signals for gas and cholesterol. Whether this slows disease or extends life is unsettled. The same non-selective binding blunts nutrients and medicines, causing constipation and dark stools. (Full Review)

Protocol

Emergency Toxicology (SDAC)
~50 g single dose
As soon as feasible after ingestion; ~1 g/kg in children. Supervised medical use.
Uremic-Toxin Reduction (AST-120)
~6 g per day
Split into three doses, between meals and apart from medications; individually tailored.
Consumer Symptomatic Use
A few hundred mg–1 g
Per dose, taken as needed for gas; no evidence-based standing daily dose.
Time to effect
Acute Binding
Immediate
Within the same digestive transit (hours) for gas and swallowed substances.
Kidney-Toxin Reduction
Days to weeks
Measurable falls in indoxyl sulfate over consistent dosing.
Downstream Clinical Effect
Months
Any downstream clinical effect, if real, would take months.

Benefits

Contraindications
  • Reduced consciousness or unprotected airway (Glasgow Coma Scale below 8)
  • Known or suspected bowel obstruction, perforation, or ileus
  • Recent gastrointestinal surgery
  • Corrosive or hydrocarbon ingestion
Key Interactions
  • Prescription drugs (levothyroxine, oral contraceptives, immunosuppressants, antiepileptics, digoxin, warfarin, tricyclics)
  • OTC medications (analgesics, antihistamines)
  • Supplements (fat-soluble vitamins A, D, E, K, minerals, botanicals)
  • Other intestinal binders (cholestyramine, colesevelam, bentonite, fiber)
  • Poorly bound (ethanol, methanol, lithium, iron, strong acids/bases)

Risk & Side Effects

  • High: Constipation and bowel changes; impaired absorption of medications, nutrients, and supplements
  • Medium: Pulmonary aspiration and aspiration pneumonitis; dental enamel abrasion and gum damage
  • Low: Bowel obstruction, bezoar, and pseudo-obstruction; fluid, electrolyte, and ocular complications
  • Speculative: Long-term microbiome and micronutrient depletion

Monitoring

Marker Target Why
Serum indoxyl sulfate As low as achievable; < ~0.6 mg/dL total Primary target of the kidney-toxin use; tracks binding effect
Estimated glomerular filtration rate (eGFR) > 60 mL/min/1.73 m² Gauges kidney function and whether toxin-binding is warranted
Serum creatinine ~0.6–1.1 mg/dL Complements eGFR for kidney trajectory
Fat-soluble vitamins (A, D, E, K) Mid-normal or better (e.g., vitamin D 40–60 ng/mL) Detects depletion from chronic non-selective binding
Serum potassium 4.0–4.5 mmol/L Screens for electrolyte shifts, esp. with cathartic use
Serum phosphate 2.5–4.5 mg/dL Relevant in kidney disease and with binder stacking
Ferritin / iron studies Ferritin ~50–150 ng/mL Iron is poorly bound but chronic use plus poor intake can lower stores
LDL cholesterol < 100 mg/dL (lower if higher risk) Tracks the cholesterol-binding effect if that is a goal

Cadence: Chronic users: reassess at ~3 months after starting, then every 6–12 months. Kidney-toxin use: toxin and kidney markers every 1–3 months early on.

Qualitative Assessment

  • Bowel regularity and stool comfort (watching for constipation or, with laxatives, diarrhea)
  • Bloating and gas symptom relief, if that is the target
  • Energy and general well-being, watching for signs of nutrient depletion over time
  • Absence of unexplained loss of effect from other medications (a warning sign of interaction)